Gyroscope complements dry AMD

Gyroscope's one-shot dry AMD therapy supplies an upstream complement factor

Gyroscope Therapeutics Ltd.’s complement-targeting gene therapy for dry age-related macular degeneration could have an edge over competing therapies that are dosed chronically or target complement downstream of its key immune mediators.

On Feb. 19, Gyroscope began Phase I/II testing of GT005, an undisclosed complement gene encoded in an adeno-associated viral (AAV) vector and administered via subretinal injection, for dry AMD. Syncona Ltd. launched Gyroscope

Read the full 642 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE